Dublin, Jan. 28, 2025 (GLOBE NEWSWIRE) — The “Cancer Immunotherapy Market Report 2025” has been added to ResearchAndMarkets.com’s offering.
This Cancer Immunotherapy market report covers market characteristics, size & growth, segmentation, regional & country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The cancer immunotherapy market size has grown rapidly in recent years. It will grow from $110.91 billion in 2024 to $125.68 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to rising prevalence of cancer, increased adoption of immunotherapy over traditional therapy, growing R&D activities for the development of targeted diseases, increased effectivity and accuracy of newer therapies, growing recognition of the limitations of traditional cancer treatments.
The cancer immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $194.64 billion in 2029 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to increasing approval of novel immunotherapies for cancer treatment, growing demand for personalized medicine, rising cases of people being detected with cancer, increasing investment in clinical trials to introduce cutting-edge treatments, growing awareness about cancer immunotherapy. Major trends in the forecast period include emergence of adoptive cell therapies, including car-t cells, exploration of oncolytic viruses in cancer immunotherapy, development of personalized cancer vaccines, utilization of artificial intelligence in immunotherapy research, increasing emphasis on real-world evidence and patient outcomes in treatment decisions.
The rise in cancer incidence is expected to propel the cancer immunotherapy market. The increasing emergence of biosimilars is expected to propel the growth of the cancer immunotherapy market in the coming years. Advanced technologies used in cancer immunotherapy are a key trend gaining popularity in the cancer immunotherapy market.
Major companies operating in the cancer immunotherapy market are focusing on developing innovative products, such as Imjudo in combination with Imfinzi, to better meet the needs of their existing consumers.
In July 2024, Boehringer Ingelheim, a pharmaceutical company based in Germany, acquired Nerio Therapeutics for $1.3 billion. This acquisition will greatly strengthen Boehringer Ingelheim’s immuno-oncology portfolio by incorporating Nerio’s innovative preclinical program centered on immune checkpoint inhibitors. Nerio Therapeutics, a biotech company located in the US, specializes in drug discovery and development, particularly focusing on phosphatases, which are a challenging but highly promising class of therapeutic protein targets.
North America was the largest region in the cancer immunotherapy market in 2024 and is also expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
Report Scope
Markets Covered:
1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy
2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma
3) By End User: Hospitals, Cancer Research Centers, Clinics
Subsegments:
1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies; Humanized Monoclonal Antibodies; Fully Human Monoclonal Antibodies
2) By Checkpoint Inhibitors: PD-1 Inhibitors; PD-L1 Inhibitors; CTLA-4 Inhibitors
3) By Immunomodulators: Cytokines; Oncolytic Viruses; Toll-Like Receptor (TLR) Agonists
4) By Vaccines: Preventive Cancer Vaccines; Therapeutic Cancer Vaccines
5) By Cell Therapy: CAR T-Cell Therapy; TCR Therapy; Natural Killer (NK) Cell Therapy
Key Companies Profiled: Amgen Inc.; AstraZeneca PLC; F. Hoffmann-La Roche Ltd; Bayer AG; Eli Lilly and Company
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2025-2029 |
| Estimated Market Value (USD) in 2025 | $125.68 Billion |
| Forecasted Market Value (USD) by 2029 | $194.64 Billion |
| Compound Annual Growth Rate | 11.6% |
| Regions Covered | Global |
The major companies featured in this Cancer Immunotherapy market report include:
- Amgen Inc.
- AstraZeneca PLC
- F. Hoffmann-La Roche Ltd
- Bayer AG
- Eli Lilly and Company
- 3D Signatures Inc.
- Adaptive Biotechnologies Corp.
- Argos Therapeutics Inc.
- Bristol-Myers Squibb Company
- Cell Medica Limited
- Cellular Biomedicine Group Inc.
- Gilead Sciences Inc.
- Gradalis Inc.
- Immatics Biotechnologies GmbH
- Iovance Biotherapeutics Inc.
- Juno Therapeutics LLC
- Kura Oncology Inc.
- MacroGenics Inc.
- Merck & Co. Inc.
- Neon Therapeutics Inc.
- Neovii Biotech GmbH
- Novartis International AG
- Pfizer Inc.
- Pulse Biosciences Inc.
- Regeneron Pharmaceuticals Inc.
- Roche Holding AG
- Targovax ASA
- Tessa Therapeutics Pte Ltd.
- TILT Biotherapeutics Ltd.
- Turnstone Biologics Corp.
- Xencor Inc.
For more information about this report visit https://www.researchandmarkets.com/r/kklbuo
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Cancer Immunotherapy Market
